Mitotane, Adrenolitic Drug, Inhibits Cell Survival and Function of Several Pituitary Cytotypes

#1163

Introduction: Mitotane (DDD) is an adrenolytic agent that is used for the treatment of adrenocortical carcinoma. We previously demonstrated that DDD affects thyrotrope cell viability and function. These data represent a possible explanation of the biochemical picture consistent with central hypothyroidism in patients undergoing DDD therapy. DDD also inhibits corticotrope cell viability by inducing caspase-mediated apoptosis and reduces POMC expression as well as basal and CRH-induced ACTH secretion. Cells originating from tissues different from pituitary are not sensitive to the inhibitory effects of DDD. Our data suggest that DDD inhibits cell survival and function of many pituitary cytotypes, acting with a generalized, but specific, toxic effect. The majority of male patients undergoing adjuvant DDD therapy show a clinical picture of hypogonadism, characterized by low free testosterone and unmodified LH concentration

Aim(s): We investigated whether mitotane may affect gonadotroph cells.

Materials and methods: We evaluated cell viability, apoptosis, cell cycle and hormonal secretion.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Gentilin E

Authors: Gentilin E, Gagliano T, Benfini K, Di Pasquale C, Falletta S,

Keywords: mitotane, adrenocortical cancer, pituitary,